Global Acoustic Neuroma Market Overview
Acoustic Neuroma Market Size was valued at USD 1.9 Billion in 2023. The Global Acoustic Neuroma industry is projected to grow from USD 2.7 Billion in 2024 to USD 4.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.43% during the forecast period (2024 - 2032).Â
An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.

Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.
Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the acoustic neuroma market.
Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore, these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).
The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.
Intended Audience
- Acoustic Neuroma Drug Suppliers
- Acoustic Neuroma Drug Manufacturers
- Research And Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Acoustic Neuroma Market Segmentation
The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.
Acoustic Neuroma Type Insights
On the basis of type, the Acoustic Neuroma Market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.
Acoustic Neuroma Diagnosis Insights
On the basis of diagnosis, the Acoustic Neuroma Market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.
Acoustic Neuroma Drug Class Insights
On the basis of drug class, the Acoustic Neuroma Market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.
Acoustic Neuroma Treatment Insights
On the basis of treatment, the Acoustic Neuroma Markett is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is subsegmented radiosurgery, craniotomy, and microsurgery removal.
Acoustic Neuroma End-User Insights
On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.
Acoustic Neuroma Regional Insights
The acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America is projected to hold the largest share of the acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).
The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.
Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.
Acoustic Neuroma Market Key Players
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.
Some of key the players in the acoustic neuroma market are:Â
- Philips Healthcare (U.S.)
- Shimadzu Corporation (Japan)
- Toshiba Medical Systems Corporation (Japan)
Acoustic Neuroma Market Industry Developments
- Q2 2024: Elekta receives FDA clearance for Leksell Gamma Knife Lightning for radiosurgery Elekta announced FDA clearance for its Leksell Gamma Knife Lightning software, which enhances precision in radiosurgery for conditions including acoustic neuroma. The approval enables expanded use of the system in U.S. neurosurgical centers.
- Q1 2024: Pfizer appoints Dr. Susan Hockfield to Board of Directors Pfizer announced the appointment of Dr. Susan Hockfield, a neuroscientist, to its Board of Directors, strengthening its expertise in neurological disorders including acoustic neuroma.
- Q2 2024: Roche launches new diagnostic imaging platform for cranial nerve tumors Roche introduced a new imaging platform designed to improve early detection of cranial nerve tumors such as acoustic neuroma, aiming to support more accurate diagnosis and treatment planning.
- Q2 2024: Natus Medical opens new neurodiagnostic facility in Boston Natus Medical Incorporated announced the opening of a new neurodiagnostic center in Boston, expanding access to advanced diagnostic services for patients with acoustic neuroma and other neurological conditions.
- Q3 2024: Elekta partners with Mayo Clinic for radiosurgery research in acoustic neuroma Elekta entered a research partnership with Mayo Clinic to advance radiosurgery techniques for acoustic neuroma, focusing on improving patient outcomes and treatment precision.
- Q2 2025: Amgen announces acquisition of neuro-oncology startup focused on acoustic neuroma therapies Amgen completed the acquisition of a neuro-oncology startup developing targeted therapies for acoustic neuroma, expanding its portfolio in neurological disease treatment.
- Q1 2025: Elekta raises $200M in public offering to expand radiosurgery business Elekta raised $200 million in a public offering to support the expansion of its radiosurgery business, including technologies for treating acoustic neuroma.
- Q2 2025: Pfizer announces partnership with University of California for acoustic neuroma research Pfizer entered a partnership with the University of California to conduct research on novel therapies for acoustic neuroma, aiming to accelerate drug development in the field.
- Q2 2024: Roche receives CE mark for new MRI contrast agent for cranial nerve tumor imaging Roche received CE mark approval for its new MRI contrast agent, designed to improve imaging of cranial nerve tumors such as acoustic neuroma in European markets.
- Q3 2024: Natus Medical secures contract with NHS for neurodiagnostic equipment Natus Medical secured a contract with the UK National Health Service to supply neurodiagnostic equipment for the detection and monitoring of acoustic neuroma.
- Q1 2025: Startup NeuroSurg raises $50M Series B to develop minimally invasive acoustic neuroma treatment NeuroSurg, a medical technology startup, raised $50 million in Series B funding to advance development of minimally invasive treatments for acoustic neuroma.
- Q2 2025: Elekta files patent for new radiosurgery device targeting acoustic neuroma Elekta filed a patent for a new radiosurgery device specifically designed for the treatment of acoustic neuroma, aiming to improve precision and patient safety.
Attribute/Metric |
Details |
Market Size 2023 |
1.9 (USD Billion) |
Market Size 2024 |
2.7 (USD Billion) |
Market Size 2032 |
4.3 (USD Billion) |
Compound Annual Growth Rate (CAGR) |
9.43 % (2024 - 2032) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year |
2023 |
Market Forecast Period |
2024 - 2032 |
Historical Data |
2019 - 2023 |
  Geographies Covered |
North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
  Key Vendors |
GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others |
  Key Market Opportunities |
The key players which grants various opportunities for the acoustic neuroma market. |
  Key Market Drivers |
 Increasing cases of acoustic neurom |
Acoustic Neuroma Market Highlights:
Frequently Asked Questions (FAQ):
acoustic neuroma market is expected to expand exponentially at 9.34% CAGR from 2024 to 2032.
acoustic neuroma market is driven by the increasing cases of acoustic neurom
Diagnosis of acoustic neuroma by gadolinium enhanced magnetic resonance imaging (MRI) is expected to be beneficial to the global acoustic neuroma market in the coming years.
The probability of severe headaches after surgery can impede by the global acoustic neuroma market growth.
North America can dominate the global acoustic neuroma market till 2025.
Pfizer Inc., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ag, Toshiba Medical Systems Corporation, GE Healthcare, Philips Healthcare, Shimadzu Corporation, and Siemens Healthcare are notable players currently working in the global acoustic neuroma market.